一、与辉瑞达成重要协议,创新价值得到体现三生制药及其子公司于2025年5月20日与辉瑞签署了一项重要协议,授予其自主研发的双特异性抗体SSGJ-707全球(不包括中国内地)开发和商业化权利。根据协议,三生制药将获得12.5亿美元首付款,以及最高可达48亿美元的里程碑付款,同时还将从授权地区的销售中收取两位数百分比的梯度分成。此外,辉瑞将以1亿美元认购公司普通股股份。这一合作不仅彰显了三生制药在药物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.